Stay updated on Nusinersen Safety in SMA Clinical Trial
Sign up to get notified when there's something new on the Nusinersen Safety in SMA Clinical Trial page.

Latest updates to the Nusinersen Safety in SMA Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include the term 'Spinal Muscular Atrophy' and a new EudraCT number, while significant details regarding the study's objectives and inclusion/exclusion criteria have been removed.SummaryDifference18%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated to version 2.14.3, replacing the previous version 2.14.2.SummaryDifference0.0%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.8%
- Check87 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference0.8%
Stay in the know with updates to Nusinersen Safety in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nusinersen Safety in SMA Clinical Trial page.